Tt c cc cy ny u c cha cht c acid aristolochic gy tn thng thn, suy thn nhng ng ngi l nhng loi cy ny ang c mt s ngi ly ngm ru ung vi mc ch cha bnh, tm b
Clinical Data Clinical Trial Results 28.7% Average Weight Loss 68 weeks 58.6% Achieved 25%+ Loss of participants 445 Trial Participants Phase 3 Data from the Phase 3 TRIUMPH-4 trial of retatrutide, reported by Eli Lilly (topline, 2025)
While GLP-1 agonists are primarily administered via subcutaneous injections, efforts are underway to develop alternative delivery methods, such as oral formulations and once-weekly injections, to improve patient adherence and convenience
Tina Moore highlights a new opinion piece in Diabetes Care that challenges the standard approach to GLP-1 medications like semaglutide
Minoxidil has been in clinical use for over 45 years, and glutathione has been marketed as a dietary supplement for decades